Merck's remigromig met primary endpoint in pivotal phase 2b/3 diabetic macular edema study
MRK•Merck said remigromig met the primary endpoint in its phase 2b/3 BRUNELLO study and both doses were non-inferior to ranibizumab for best-corrected visual acuity at week 52. The company reported higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and discontinuations with remigromig; both doses were generally well tolerated.
1. Study results
Merck said both remigromig doses demonstrated non-inferiority to ranibizumab for best-corrected visual acuity at 52 weeks in the pivotal phase 2b/3 BRUNELLO study of adults with diabetic macular edema. Higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and discontinuations were reported with remigromig, while both doses were generally well tolerated.
